Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus

PharmacoEconomics

Volumn 33, Issue 4, 2015, Pages 285-325

  Antonanzas, Fernando ^a   Lozano, Carmen ^a   Torres, Carmen ^a  

^a UNIVERSITY OF LA RIOJA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; HUMAN; ISOLATION AND PURIFICATION; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; HUMANS; LENGTH OF STAY; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84939986716     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0242-y     Document Type: Article

References (109)

1. Goldsack JC, DeRitter C, Power M, et al. Clinical, patient experience and cost impacts of performing active surveillance on known methicillin-resistant Staphylococcus aureus positive patients admitted to medical–surgical units. Am J Infect Control. 2014;42:1039–43.
2. Nulens E, Broex E, Ament A, et al. Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital. J Hosp Infect. 2008;68:301–7.
3. Köck R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15:19688.
4. Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcusaureus (MRSA) and its control. Int J Antimicrob Agents. 2006;28:379–84.
5. Gould IM, Reilly J, Bunyan D, et al. Costs of healthcare-associated methicillin-resistant Staphylococcusaureus and its control. Clin Microbiol Infect. 2010;16:1721–8.
6. Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcusaureus: review and analysis of the literature. Pharmacoeconomics. 2007;25:751–68.
7. Chen AF, Wessel CB, Rao N. Staphylococcusaureus screening and decolonization in orthopaedic surgery and reduction of surgical site infections. Clin Orthop Relat Res. 2013;471:2383–99.
8. Farbman L, Avni T, Rubinovitch B, et al. Cost–benefit of infection control interventions targeting methicillin-resistant Staphylococcusaureus in hospitals: systematic review. Clin Microbiol Infect. 2013;19:E582–93.
9. Korczak D, Schöffmann C. Medical and health economic evaluation of prevention- and control measures related to MRSA infections or -colonisations at hospitals. GMS Health Technol Assess. 2010;6:Doc04.
10. McGinigle KL, Gourlay ML, Buchanan IB. The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality, and costs: a systematic review. Clin Infect Dis. 2008;46:1717–25.
11. Brown J, Paladino JA. Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model. Pharmacoeconomics. 2010;28:567–75.
12. Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist. 2012;5:87–102.
13. Gurasamy KS, Koti R, Toon CD, et al. Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds. Cochrane Database Syst Rev. 2013;11:CD010427.
14. Watkins RR, Lemonovich TL, File TM Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012;7:131–43.
15. Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev. 2013;7:CD008056.
16. European Centre for Disease Prevention and Control (ECDC)/European Medicines Agency (EMEA). The bacterial challenge: time to react, 2009. In: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf.
17. Centers of Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. In: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
18. European Centre for Disease Prevention and Control (ECDC), 2013. Summary of the latest data on antibiotic resistance in the European Union. In: http://www.ecdc.europa.eu/en/eaad/Documents/EARS-Net-summary.pdf.
19. García-Álvarez L, Holden MT, Lindsay H, et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis. 2011;11:595–603.
20. Gómez P, González-Barrio D, Benito D, et al. Detection of methicillin-resistant Staphylococcus aureus (MRSA) carrying the mecC gene in wild small mammals in Spain. J Antimicrob Chemother. 2014;2014(69):2061–4.
21. Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013;68:4–11.
22. Hayden MK, Rezai K, Hayes RA, et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285–7.
23. Lozano C, Gómez-Sanz E, Benito D, et al. Staphylococcus aureus nasal carriage, virulence traits, antibiotic resistance mechanisms, and genetic lineages in healthy humans in Spain, with detection of CC398 and CC97 strains. Int J Med Microbiol. 2011;301:500–5.
24. Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004;364:703–5.
25. Simor AE. Loeb M; CIDS/CAMM Guidelines Committee. The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: a CIDS/CAMM position paper. Can J Infect Dis. 2004;15:39–48.
26. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother. 2009;64:44–6.
27. Cercenado E, Cuevas O, Marín M, et al. Community-acquired methicillin-resistant Staphylococcus aureus in Madrid, Spain: transcontinental importation and polyclonal emergence of Panton–Valentine leukocidin positive isolates. Diagn Microbiol Infect Dis. 2008;61:143–9.
28. Gómez-Sanz E, Torres C, Lozano C, et al. Detection, molecular characterization, and clonal diversity of methicillin-resistant Staphylococcus aureus CC398 and CC97 in Spanish slaughter pigs of different age groups. Foodborne Pathog Dis. 2010;7:1269–77.
29. Khanna T, Friendship R, Dewey C, et al. Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers. Vet Microbiol. 2008;128:298–303.
30. Lozano C, Aspiroz C, Ezpeleta AI, et al. Empyema caused by MRSA ST398 with atypical resistance profile, Spain. Emerg Infect Dis. 2011;17:138–40.
31. Lozano C, Rezusta A, Gómez P, et al. High prevalence of spa types associated with the clonal lineage CC398 among tetracycline-resistant methicillin-resistant Staphylococcus aureus strains in a Spanish hospital. J Antimicrob Chemother. 2012;67:330–4.
32. Wulf MW, Markestein A, van der Linden FT, et al. First outbreak of methicillin-resistant Staphylococcus aureus ST398 in a Dutch hospital, June 2007. Euro Surveill. 2008 Feb 28;13(9). pii: 8051.
33. European Food Safety Autority (EFSA). Assessment of the public health significance of meticillin resistant Staphylococcus aureus (MRSA) in animals and foods. EFSA J. 2009;993:1–73.
34. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999;20:408–11.
35. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One. 2009;4:e8305.
36. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol. 2009;30:453–60.
37. Erdem G, Salazar R, Kimata C, et al. Staphylococcus aureus osteomyelitis in Hawaii. Clin Pediatr (Phila). 2010;49:477–84.
38. Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, Lesher LJ, Lynfield R. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31:365–73.
39. Kaye KS, Engemann JJ, Mozaffari E, et al. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis. 2004;10:1125–8.
40. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother. 2004;38:1377–82.
41. de Kraker ME, Wolkewitz M, Davey PG, et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2011;55:1598–605.
42. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005;52:113–22.
43. Rubio-Terrés C, Garau J, Grau S, et al. Cost of bacteraemia caused by methicillin-resistant vs methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect. 2010;16:722–8.
44. Shorr AF, Tabak YP, Gupta V, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10:R97.
45. Gómez-Pavón J, RodríguezSalazar J, de la Fernández Puente E, et al. Staphylococcus aureus infection in an acute geriatric unit. Rev Esp Geriatr Gerontol. 2010;45:5–9.
46. Athanasakis K, Petrakis I, Ollandezos M, et al. Antibacterial treatment of meticillin-resistant Staphylococcus aureus complicated skin and soft tissue infections: a cost and budget impact analysis in Greek hospitals. Infect Dis Ther. Epub 2014 Oct 7.
47. Angelis G, Allignol A, Murthy A, et al. Multistate modelling to estimate the excess length of stay associated with meticillin-resistant Staphylococcus aureus colonisation and infection in surgical patients. J Hosp Infect. 2011;78:86–91.
48. Goetghebeur M, Landry PA, Han D, et al. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol. 2007;18:27–34.
49. Hübner C, Hübner NO, Hopert K, et al. Analysis of MRSA-attributed costs of hospitalized patients in Germany. Eur J Clin Microbiol Infect Dis. 2014;33:1817–22.
50. Kanerva M, Blom M, Tuominen U, et al. Costs of an outbreak of meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2007;66:22–8.
51. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol. 2001;22:99–104.
52. de Kraker ME, Davey PG, Grundmann H, et al. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8:e1001104.
53. Labreche MJ, Lee GC, Attridge RT, et al. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med. 2013;26:508–17.
54. Lee BY, Singh A, David MZ, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2013;19:528–36.
55. Macedo-Viñas M, De Angelis G, Rohner P, et al. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss university hospital: excess length of stay and costs. J Hosp Infect. 2013;84:132–7.
56. Ramanathan V, Chiu EJ, Thomas JT, Khan A, Dolson GM, Darouiche RO. Healthcare costs associated with hemodialysis catheter-related infections: a single-center experience. Infect Control Hosp Epidemiol. 2007;28:606–9.
57. Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ. 2009;10:287–97.
58. Schultz ED, Tanaka DT, Goldberg RN, et al. Effect of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit on total hospital cost. Infect Control Hosp Epidemiol. 2009;30:383–5.
59. Smith RD, Yago M, Millar M, et al. A macroeconomic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin-resistant Staphylococcus aureus (MRSA). Appl Health Econ Health Policy. 2006;5:55–65.
60. Watters K, O’Dwyer TP, Rowley H. Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences? J Laryngol Otol. 2004;118:694–9.
61. Weigelt JA, Lipsky BA, Tabak YP, et al. Surgical site infections: causative pathogens and associated outcomes. Am J Infect Control. 2010;38:112–20.
62. Clancy CJ, Bartsch SM, Nguyen MH, et al. A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart–lung transplant recipients. Eur J Clin Microbiol Infect Dis. 2014;33:1053–61.
63. Courville XF, Tomek IM, Kirkland KB, et al. Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2012;33:152–9.
64. Diller R, Sonntag AK, Mellmann A, et al. Evidence for cost reduction based on pre-admission MRSA screening in general surgery. Int J Hyg Environ Health. 2008;211:205–12.
65. Elliott RA, Weatherly HL, Hawkins NS, et al. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptides antibiotic prophylaxis? Eur J Health Econ. 2010;11:57–66.
66. Gurieva T, Bootsma MC, Bonten MJ. Cost and effects of different admission screening strategies to control the spread of methicillin-resistant Staphylococcus aureus. PLoS Comput Biol. 2013;9:e1002874.
67. Huang SS, Septimus E, Avery TR, et al. Cost savings of universal decolonization to prevent intensive care unit infection: implications of the reduce MRSA trial. Infect Control Hosp Epidemiol. 2014;35:S23–31.
68. Lee BY, Tsui BY, Bailey RR, et al. Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol. 2009;30:1158–65.
69. Lee BY, Wiringa AE, Bailey RR, et al. Screening cardiac surgery patients for MRSA: an economic computer model. Am J Manag Care. 2010;16:e163–73.
70. Lee BY, Wiringa AE, Bailey RR, et al. The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2010;31:1130–8.
71. Lee BY, Song Y, McGlone SM, et al. The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA. Clin Microbiol Infect. 2011;17:1717–26.
72. Mueller SW, Krebsbach LE. Impact of an antimicrobial-impregnated gauze dressing on surgical site infections including methicillin-resistant Staphylococcus aureus infections. Am J Infect Control. 2008;36:651–5.
73. Nelson RE, Samore MH, Smith KJ, et al. Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers. Clin Microbiol Infect. 2010;16:1740–6.
74. Noskin GA, Rubin RJ, Schentag JJ, et al. Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals. Infect Control Hosp Epidemiol. 2008;29:16–24.
75. Olchanski N, Mathews C, Fusfeld L, et al. Assessment of the influence of test characteristics on the clinical and cost impacts of methicillin-resistant Staphylococcus aureus screening programs in US hospitals. Infect Control Hosp Epidemiol. 2011;32:250–7.
76. Petlin A, Schallom M, Prentice D, et al. Chlorhexidine gluconate bathing to reduce methicillin-resistant Staphylococcus aureus acquisition. Crit Care Nurse. 2014;34:17–24.
77. Robotham JV, Graves N, Cookson BD, et al. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ. 2011;343:d5694.
78. Wassenberg MW, de Wit GA, Bonten MJ. Cost-effectiveness of preoperative screening and eradication of Staphylococcus aureus carriage. PLoS One. 2011;6:e14815.
79. You JH, Chan CY, Wong MY, et al. Active surveillance and decolonization of methicillin-resistant Staphylococcus aureus on admission to neonatal intensive care units in Hong Kong: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2012;33:1024–30.
80. van Hal SJ, Stark D, Lockwood B, et al. Methicillin-resistant Staphylococcus aureus (MRSA) detection: comparison of two molecular methods (IDI-MRSAPCR assay and GenoType MRSA Direct PCR assay) with three selective MRSA agars (MRSA ID, MRSASelect, andCHROMagar MRSA) for use with infection-control swabs. J Clin Microbiol. 2007;45:2486–90.
81. Henson G, Ghonim E, Swiatlo A, et al. Cost–benefit and effectiveness analysis of rapid testing for MRSA carriage in a hospital setting. Clin Lab Sci. 2014;27:13–20.
82. Shrestha NK, Shermock KM, Gordon SM, et al. Predictive value and cost-effectiveness analysis of a rapid polymerase chain reaction for preoperative detection of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol. 2003;24:327–33.
83. ®S. aureus and Xpert MRSA/SA Assay. Diagn Microbiol Infect Dis. 2014;78:352–5.
84. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315–20.
85. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200.
86. Hope R, Blackburn RM, Verlander NQ, et al. Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context. J Antimicrob Chemother. 2013;68:2641–7.
87. Rojas L, Bunsow E, Muñoz P, et al. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients. J Antimicrob Chemother. 2012;67:1760–8.
88. Walraven CJ, North MS, Marr-Lyon L, et al. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011;66:2368–92.
89. Seaton RA, Johal S, Coia JE, et al. Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. Eur J Clin Microbiol Infect Dis. 2014;33:305–11.
90. Stephens JM, Gao X, Patel DA, et al. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013;5:447–57.
91. Eckmanna C, Lawson W, Nathwani D, et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014;44:56–64.
92. Nathwani D, Eckmann C, Lawson W, et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect. 2014 (in press).
93. Bounthavong M, Zargarzadeh A, Hsu DI, et al. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health. 2011;14:631–9.
94. Brown J, Brown KA, Forrest A. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis. Clin Ther. 2011;33:1475–82.
95. Campbell ML, Marchaim D, Pogue JM, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother. 2012;46:1587–97.
96. De Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection. 2009;37:123–32.
97. Kullar R, Davis SL, Taylor TN, et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012;32:195–201.
98. Kullar R, Davis SL, Kaye KS, et al. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy. 2013;33:3–10.
99. Laohavaleeson S, Barriere SL, Nicolau DP, et al. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008;28:1471–82.
100. Lipsky BA, Napolitano LM, Moran GJ, et al. Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study. Diagn Microbiol Infect Dis. 2014;79:266–72.
101. McKinnon PS, Sorensen SV, Liu LZ, et al. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother. 2006;40:1017–23.
102. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, et al. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw (Online). 2007;61:461–5.
103. Patel DA, Shorr AF, Chastre J, et al. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Crit Care. 2014;18:R157.
104. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189:425–8.
105. Rosner AJ, Becker DL, Wong AH, et al. The costs and consequences of methicillin-resistant Staphylococcus aureus infection treatments in Canada. Can J Infect Dis Med Microbiol. 2004;15:213–20.
106. Rubio-Terrés C, Rubio-Rodríguez D, Majos N, et al. Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin. Rev Esp Quimioter. 2012;25:283–92.
107. Schürmann D, Sorensen SV, De Cock E, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ. 2009;10:65–79.
108. Wright BM, Eiland EH 3rd. Retrospective analysis of clinical and cost outcomes associated with methicillin-resistant Staphylococcus aureus complicated skin and skin structure infections treated with daptomycin, vancomycin, or linezolid. J Pathog. 2011;2011:347969.
109. Young MJ, Hodges G, McCardle JE. Cost avoidance using linezolid for methicillin-resistant Staphylococcus aureus infections in a specialist diabetes foot clinic. J Antimicrob Chemother. 2012;67:2974–5.